Teratogenic effect of hydroxyethylrutoside, a flavonoid derivate drug – a population-based case–control study

References

• Galati G, Sabzevari O, Wilson JX, O’Brien PJ. Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics. Toxicology 2002;177:91–104
   PubMed Web of Science ®Google Scholar
• Jacobs H, Moalin M, van Gisbergen MW, et al. An essential difference in the reactivity of the glutathione adducts of the structurally closely related flavonoids monoHER and quercetin. Free Radic Biol Med 2011;51:2118–23
   PubMedGoogle Scholar
• Jacobs H, van der Vijgh WJ, Koek GH, et al. Characterization of the glutathione conjugate of the semisynthetic flavonoid monoHER. Free Radic Biol Med 2009;46:1567–73
   PubMedGoogle Scholar
• Rusznyak S, Szent-Györgyi A. Vitamin P: flavonals as vitamins. Nature 1936;138:27
   Google Scholar
• Borvendég J. Gyógyszer compendium. (Hungarian). In: Borvendég J, ed. Gyógyszer compendium. Budapest: Havas MediMedia Információs KFT; 2000
   Google Scholar
• Kienzler JL, Sallin D, Schifflers MH, Ghika A. Pharmacokinetics of mono-3′- and mono-4′-0-(beta-hydroxyethyl)-rutoside derivatives, after single doses of Venoruton powder in healthy volunteers. Eur J Clin Pharmacol 2002;58:395–402
   PubMedGoogle Scholar
• Wadworth AN, Faulds D. Hydroxyethylrutosides. A review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders. Drugs 1992;44:1013–32
   PubMed Web of Science ®Google Scholar
• Petruzzellis V, Troccoli T, Candiani C, et al. Oxerutins (Venoruton): efficacy in chronic venous insufficiency–a double-blind, randomized, controlled study. Angiology 2002;53:257–63
   PubMedGoogle Scholar
• Cesarone MR, Belcaro G, Pellegrini L, et al. HR, 0-(beta-hydroxyethyl)-rutosides; (Venoruton): rapid relief of signs/symptoms in chronic venous insufficiency and microangiopathy: a prospective, controlled study. Angiology 2005;56:165–72
   PubMedGoogle Scholar
• Cesarone MR, Belcaro G, Ricci A, et al. Prevention of edema and flight microangiopathy with Venoruton (HR), (0-[beta-hydroxyethyl]-rutosides) in patients with varicose veins. Angiology 2005;56:289–93
   PubMed Web of Science ®Google Scholar
• Ippolito E, Belcaro G, Dugall M, et al. Venoruton(R): post thrombotic syndrome. Clinical improvement in venous insufficiency (signs and symptoms) with Venoruton(R). A five-year, open-registry, efficacy study. Panminerva Med 2011;53:13–9
   PubMedGoogle Scholar
• Banhidy F, Acs N, Puho EH, Czeizel AE. Varicose veins of lower extremities in pregnant women and birth outcomes. Cent Eur J Public Health 2010;18:161–8
   PubMedGoogle Scholar
• Bánhidy F, Ács N, Puhó HE, Czeizel AE. Possible association of materanal hemorrhoid with congenital abnormalities in their children: a population-based case-control study. Balkan J Med Genet 2010;13:23–33
   Google Scholar
• Acs N, Banhidy F, Puho EH, Czeizel AE. No association between severe constipation with related drug treatment in pregnant women and congenital abnormalities in their offspring: a population-based case-control study. Congenit Anom (Kyoto) 2010;50:15–20
   PubMedGoogle Scholar
• Bergstein NA. Clinical study on the efficacy of O-(beta-hydroxyethyl)rutoside (HR) in varicosis of pregnancy. J Int Med Res 1975;3:189–93
   PubMedGoogle Scholar
• Wijayanegara H, Mose JC, Achmad L, et al. A clinical trial of hydroxyethylrutosides in the treatment of haemorrhoids of pregnancy. J Int Med Res 1992;20:54–60
   PubMed Web of Science ®Google Scholar
• Sohn C, Jahnichen C, Bastert G. [Effectiveness of beta-hydroxyethylrutoside in patients with varicose veins in pregnancy]. Zentralbl Gynakol 1995;117:190–7
   PubMedGoogle Scholar
• Titapant V, Indrasukhsri B, Lekprasert V, Boonnuch W. Trihydroxyethylrutosides in the treatment of hemorrhoids of pregnancy: a double-blind placebo-controlled trial. J Med Assoc Thai 2001;84:1395–400
   PubMedGoogle Scholar
• Young GL, Jewell D. Interventions for varicosities and leg oedema in pregnancy. Cochrane Database Syst Rev 2000;(2):CD001066
   Google Scholar
• Quijano CE, Abalos E. Conservative management of symptomatic and/or complicated haemorrhoids in pregnancy and the puerperium. Cochrane Database Syst Rev 2005;(3):CD004077
   Google Scholar
• Bamigboye AA, Smyth R. Interventions for varicose veins and leg oedema in pregnancy. Cochrane Database Syst Rev 2007;(1):CD001066
   Google Scholar
• Shepard TH, Lemire RJ. Catalog of teratogenic agents, 11th ed. Baltimore (MA): Johns Hopkins Univ Press; 2004
   Google Scholar
• Vogt G, Puho E, Czeizel AE. A population-based case-control study of isolated ocular coloboma. Ophthalmic Epidemiol 2005;12:191–7
   PubMed Web of Science ®Google Scholar
• Paput L, Banhidy F, Czeizel AE. Association of drug treatments in pregnant women with the risk of external ear congenital abnormalities in their offspring: a population-based case-control study. Congenit Anom (Kyoto) 2011;51:126–37
   PubMedGoogle Scholar
• Rockenbauer M, Siffel C, Varga E. Description and mission evaluation of the Hungarian case-control surveillance of congenital abnormalities, 1980–1996. Teratology 2001;63:176–85
   PubMedGoogle Scholar
• Czeizel AE. First 25 years of the Hungarian congenital abnormality registry. Teratology 1997;55:299–305
   PubMedGoogle Scholar
• Czeizel AE. Specified critical period of different congenital abnormalities: a new approach for human teratological studies. Congenit Anom (Kyoto) 2008;48:103–9
   PubMedGoogle Scholar
• Shaffer JP. Multiple hypothesis testing. Annu Rev Psychol 1995;46:561--84
   Google Scholar
• Chan TS, Galati G, Pannala AS, et al. Simultaneous detection of the antioxidant and pro-oxidant activity of dietary polyphenolics in a peroxidase system. Free Radic Res 2003;37:787--94
   Google Scholar
• Rockenbauer M, Olsen J, Czeizel AE, et al. Recall bias in a case-control surveillance system on the use of medicine during pregnancy. Epidemiology 2001;12:461–6
   PubMed Web of Science ®Google Scholar